Day: October 28, 2026

Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator Licenses SpeechDx Dataset to Eli Lilly and Company, Advancing Speech-Based Markers as a Critical Alzheimer’s Research Tool

Lilly's partnership signals growing industry recognition of AI-driven speech analysis as a path to predicting Alzheimer's disease riskNEW YORK, Oct....

Novato-based Live Oaks Wellness encourages year-round prevention with family engagement and community-based prevention efforts for substance abuse

National Substance Abuse Prevention Month Goes Beyond Addiction Awareness Whether you’re seeking detox, residential care, or simply a safe space...

Genmab Announces Statistically Significant, Clinically Meaningful Improvement in Overall Survival and Objective Response with Petosemtamab Combination at First Interim Analysis in First-Line R/M Patients with PD-L1+ Head and Neck Cancer

Applied Biologics Announces Publication of Peer-Reviewed CAMPX Interim Trial Results in the Journal of Chronic Wound Care Management & Research

Published multicenter clinical trial data demonstrate higher wound closure rates and greater wound area reduction with XWRAP® plus standard of...

Vivex Biologics’ VIA Disc® NP Meets Primary Endpoint in Pivotal, Sham-Controlled ASCEND Trial Published in Journal of Clinical Medicine

The first intradiscal allograft to succeed in a rigorous, sham-controlled trial for chronic lumbar discogenic pain, a leading driver of...

Nacuity Pharmaceuticals Announces First Patient Dosed in Global Confirmatory Phase 3 Trial of NPI-001 (N-acetylcysteine amide) Tablets for the Treatment of Retinitis Pigmentosa Associated with Usher Syndrome

error: Content is protected !!